Vibecotamab for measurable residual disease in acute myeloid leukemia and for myelodysplastic syndromes and chronic myelomonocytic leukemia after hypomethylating agent failure: a phase II study.

Saved in:
Bibliographic Details
Title: Vibecotamab for measurable residual disease in acute myeloid leukemia and for myelodysplastic syndromes and chronic myelomonocytic leukemia after hypomethylating agent failure: a phase II study.
Authors: Short NJ; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Unit 428, 1400 Holcombe Blvd, Houston, TX, 77030, USA. nshort@mdanderson.org., Bataller A; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Unit 428, 1400 Holcombe Blvd, Houston, TX, 77030, USA., DiNardo CD; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Unit 428, 1400 Holcombe Blvd, Houston, TX, 77030, USA., Montalban-Bravo G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Unit 428, 1400 Holcombe Blvd, Houston, TX, 77030, USA., Wang SA; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Wang W; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Maiti A; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Unit 428, 1400 Holcombe Blvd, Houston, TX, 77030, USA., Nguyen D; Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Hachem MC; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Unit 428, 1400 Holcombe Blvd, Houston, TX, 77030, USA., Bi TM; Hematopoietic Biology and Malignancy Department, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Issa GC; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Unit 428, 1400 Holcombe Blvd, Houston, TX, 77030, USA., Chien KS; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Unit 428, 1400 Holcombe Blvd, Houston, TX, 77030, USA., Ohanian M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Unit 428, 1400 Holcombe Blvd, Houston, TX, 77030, USA., Kadia TM; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Unit 428, 1400 Holcombe Blvd, Houston, TX, 77030, USA., Loghavi S; Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Karrar O; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Unit 428, 1400 Holcombe Blvd, Houston, TX, 77030, USA., Bachireddy P; Hematopoietic Biology and Malignancy Department, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Hwang H; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Huang X; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Garcia-Manero G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Unit 428, 1400 Holcombe Blvd, Houston, TX, 77030, USA., Ravandi F; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Unit 428, 1400 Holcombe Blvd, Houston, TX, 77030, USA.
Source: Journal of hematology & oncology [J Hematol Oncol] 2026 Jun 27. Date of Electronic Publication: 2026 Jun 27.
Publication Type: Journal Article
Journal Info: Publisher: Biomed Central Country of Publication: England NLM ID: 101468937 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1756-8722 (Electronic) Linking ISSN: 17568722 NLM ISO Abbreviation: J Hematol Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1756-8722
DOI:10.1186/s13045-026-01825-3